Immune to rename as Biostax, outlines strategic plans
Tashatuvango
- Immune Therapeutics (OTCPK:IMUN) said a majority of its stockholders have approved the company's name change to Biostax Corp.
- The company also unveiled a new website to introduce the initial phase of its strategic plan wherein it will operate as a hub-and-spoke development engine powering small-scale med-tech, pharmaceutical and biotechnology programs.
- The company aims to focus on ex-US and emerging market commercial development; developing recently licensed JKB-122 for treating autoimmune hepatitis, NASH, and chronic liver disease; continue negotiations to license a late-stage Hyperphosphatemia therapy.
- The company also intends to internally develop two health-tech platforms: BiostaxRx, a telehealth and inflammaging platform, and a smart contract / Healthcare 4.0 electronic records and prescription platform; and help in developing Forte Animal Health.
- "We have reinitiated commercial efforts in the emerging Ex-US marketplace, are evaluating our US capabilities as pertaining to JKB-122, and hope to see a value translation in the coming year," said CEO Kelly Wilson.